|
ES2245778T3
(es)
*
|
1993-08-11 |
2006-01-16 |
Jenner Technologies |
Vacuna contra el cancer de prostata.
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
EP1152060B1
(en)
*
|
1998-11-18 |
2015-04-15 |
Oxford Biomedica (UK) Limited |
5T4 tumour-associated antigen for use in tumour immunotherapy
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
PT1137792E
(pt)
*
|
1998-12-09 |
2007-08-10 |
Therion Biolog Corp |
Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
|
|
EP1496939B1
(en)
*
|
2002-04-09 |
2007-08-15 |
Sanofi Pasteur Limited |
Modified cea nucleic acid and expression vectors
|
|
AU2004267117B2
(en)
*
|
2003-08-21 |
2011-01-20 |
Virax Development Pty Ltd |
Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
|
|
CA2550583C
(en)
*
|
2003-10-08 |
2013-01-15 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
AU2004289340B2
(en)
*
|
2003-11-12 |
2010-11-11 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
System for treating and preventing breast cancer
|
|
AU2004289368B2
(en)
|
2003-11-12 |
2010-08-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
CN102281892A
(zh)
|
2009-01-13 |
2011-12-14 |
特朗斯吉有限公司 |
酿酒酵母线粒体核酸级分用于免疫刺激的用途
|
|
HUE025015T2
(en)
|
2009-01-20 |
2016-04-28 |
Transgene Sa |
Soluble in ICAM-1 as a biomarker for predicting therapeutic response
|
|
DK2411815T3
(en)
|
2009-03-24 |
2015-11-30 |
Transgene Sa |
Biomarker MONITORING OF PATIENTS
|
|
US20120058493A1
(en)
|
2009-04-17 |
2012-03-08 |
Bruce Acres |
Biomarker for monitoring patients
|
|
CN102483405B
(zh)
|
2009-07-10 |
2015-12-02 |
特朗斯吉有限公司 |
用于选择患者的生物标志物及相关方法
|
|
EP2601529B8
(en)
|
2010-08-06 |
2017-01-25 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Biomarkers for predicting response to a cancer vaccine
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
KR102395820B1
(ko)
*
|
2013-11-05 |
2022-05-09 |
버베리안 노딕 에이/에스 |
종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제
|
|
EP3142689B1
(en)
|
2014-05-13 |
2020-11-11 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
|
|
KR102504758B1
(ko)
|
2014-07-16 |
2023-02-28 |
트랜스진 |
종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
|
|
CN107949397A
(zh)
|
2015-02-13 |
2018-04-20 |
特兰斯吉恩股份有限公司 |
免疫治疗疫苗和抗体组合治疗
|
|
RU2753884C2
(ru)
|
2015-07-31 |
2021-08-24 |
Бавариан Нордик А/С |
Промоторы для усиления экспрессии в поксвирусах
|
|
EP3400009A2
(en)
|
2016-01-05 |
2018-11-14 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
ES2924741T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
AU2017336269B2
(en)
|
2016-09-28 |
2022-06-16 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
EP3562946B1
(en)
|
2016-12-28 |
2021-11-24 |
Transgene SA |
Oncolytic viruses and therapeutic molecules
|
|
CN110770345A
(zh)
|
2017-04-14 |
2020-02-07 |
托尔奈公司 |
免疫调节多核苷酸、抗体缀合物及其使用方法
|
|
US11052147B2
(en)
|
2017-05-15 |
2021-07-06 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
WO2018210804A1
(en)
|
2017-05-15 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
WO2019038388A1
(en)
|
2017-08-24 |
2019-02-28 |
Bavarian Nordic A/S |
POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY
|
|
MX2020009262A
(es)
|
2018-03-07 |
2021-01-08 |
Transgene |
Vectores de parapoxvirus.
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
WO2020049151A1
(en)
|
2018-09-06 |
2020-03-12 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
US20220233607A1
(en)
|
2019-05-29 |
2022-07-28 |
Université De Tours |
Toxoplasma platform for treating cancer
|
|
EP4110830A4
(en)
|
2020-02-28 |
2024-09-11 |
Tallac Therapeutics, Inc. |
TRANSGLUTAMINASE-MEDIATED CONJUGATION
|
|
US20230114464A1
(en)
|
2020-03-12 |
2023-04-13 |
Bavarian Nordic A/S |
Conditions Improving Poxvirus Stability
|
|
JP2025528219A
(ja)
|
2022-08-18 |
2025-08-26 |
トランジェーヌ |
キメラポックスウイルス
|